HC Wainwright Has Positive Forecast for CRBP Q1 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Equities researchers at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a note issued to investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now forecasts that the biopharmaceutical company will post earnings of ($0.98) per share for the quarter, up from their previous estimate of ($1.33). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.13) EPS, FY2025 earnings at ($4.20) EPS, FY2026 earnings at ($4.57) EPS, FY2027 earnings at ($5.47) EPS, FY2028 earnings at ($4.37) EPS and FY2029 earnings at ($2.14) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.24.

A number of other research firms have also weighed in on CRBP. Piper Sandler assumed coverage on Corbus Pharmaceuticals in a research note on Monday, December 2nd. They issued an “overweight” rating and a $35.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and issued a $51.00 price objective on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. Jefferies Financial Group dropped their price target on Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. StockNews.com raised Corbus Pharmaceuticals to a “sell” rating in a research note on Thursday, March 6th. Finally, William Blair initiated coverage on Corbus Pharmaceuticals in a research note on Friday, February 28th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Corbus Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $59.13.

Corbus Pharmaceuticals Stock Performance

NASDAQ CRBP opened at $6.33 on Monday. The business’s fifty day moving average is $9.19 and its 200 day moving average is $17.71. Corbus Pharmaceuticals has a fifty-two week low of $6.26 and a fifty-two week high of $61.90. The company has a market capitalization of $77.43 million, a PE ratio of -1.35 and a beta of 2.63.

Institutional Investors Weigh In On Corbus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its position in Corbus Pharmaceuticals by 27.0% during the third quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 1,172 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Corbus Pharmaceuticals by 7.6% in the third quarter. The Manufacturers Life Insurance Company now owns 22,731 shares of the biopharmaceutical company’s stock worth $469,000 after buying an additional 1,600 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Corbus Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 2,195 shares during the period. FMR LLC raised its holdings in shares of Corbus Pharmaceuticals by 33.0% in the third quarter. FMR LLC now owns 10,028 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 2,486 shares during the period. Finally, Deutsche Bank AG raised its holdings in shares of Corbus Pharmaceuticals by 46.8% in the fourth quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 2,616 shares during the period. 64.64% of the stock is currently owned by hedge funds and other institutional investors.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.